Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections Among Critically Ill Patients

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Feb 25

PMID 36839872

Authors

Carla Troisi

Pier Giorgio Cojutti

Matteo Rinaldi

Cristiana Laici

Antonio Siniscalchi

Pierluigi Viale

Federico Pea

Affiliations

Soon will be listed here.

Abstract

Assessment of glomerular filtration rate (GFR) is necessary for dose adjustments of beta-lactam that are excreted by the kidneys, such as meropenem. The aim of this study was to compare the daily dose of 24 h-continuous infusion (CI) meropenem when GFR was calculated by means of measured creatinine clearance (mCL) or estimated by the CKDEPI (eGFR), Cockcroft-Gault (eGFR), and MDRD (eGFR) equations. Adult critically ill patients who underwent therapeutic drug monitoring (TDM) for the assessment of 24 h-CI meropenem steady state concentration (Css) and for whom a 24 h-urine collection was performed were retrospectively enrolled. Meropenem clearance (CL) was regressed against mCL, and meropenem daily dose was calculated based on the equation infusion rate = daily dose/CL. eGFR, eGFR, and eGFR were regressed against mCL in order to estimate CL. Forty-six patients who provided 133 meropenem Css were included. eGFR overestimated mCL up to 90 mL/min, then mCL was underestimated. eGFR and eGFR overestimated mCL across the entire range of GFR. In critically ill patients, dose adjustments of 24 h-CI meropenem should be based on mCL. Equations for estimation of GFR may lead to gross under/overestimates of meropenem dosages. TDM may be highly beneficial, especially for critically ill patients with augmented renal clearance.

Citing Articles

Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia.

Troisi C, Cojutti P, Rinaldi M, Tonetti T, Siniscalchi A, van Hasselt C Clin Pharmacokinet. 2024; 63(11):1573-1583.

PMID: 39455501 PMC: 11573875. DOI: 10.1007/s40262-024-01436-6.

Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.

Morales Junior R, Mizuno T, Paice K, Pavia K, Hambrick H, Tang P J Antimicrob Chemother. 2024; 79(10):2668-2677.

PMID: 39092928 PMC: 11442002. DOI: 10.1093/jac/dkae274.

Application of Monte Carlo simulation to optimise the dosage regimen of meropenem in patients with augmented renal clearance for infection.

Hou J, Zhang M, Ma S, Cong R, Li J Heliyon. 2024; 10(12):e32600.

PMID: 38975089 PMC: 11225735. DOI: 10.1016/j.heliyon.2024.e32600.

Meropenem PK/PD Variability and Renal Function: "We Go Together".

Angelini J, Giuliano S, Flammini S, Pagotto A, Lo Re F, Tascini C Pharmaceutics. 2023; 15(9).

PMID: 37765207 PMC: 10534409. DOI: 10.3390/pharmaceutics15092238.

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study.

Liu C, Cojutti P, Giannella M, Roberto M, Casadei B, Cristiano G Pharmaceutics. 2023; 15(3).

PMID: 36986882 PMC: 10059857. DOI: 10.3390/pharmaceutics15031022.

References

Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A . Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). PMC: 5967687. DOI: 10.1128/CMR.00079-17. View

Franceschi L, Cojutti P, Baraldo M, Pea F . Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014; 36(5):674-6. DOI: 10.1097/FTD.0000000000000054. View

Pea F, Viale P, Cojutti P, Furlanut M . Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012; 56(12):6343-8. PMC: 3497191. DOI: 10.1128/AAC.01291-12. View

Declercq P, Gijsen M, Meijers B, Schetz M, Nijs S, dHoore A . Reliability of serum creatinine-based formulae estimating renal function in non-critically ill surgery patients: Focus on augmented renal clearance. J Clin Pharm Ther. 2018; 43(5):695-706. DOI: 10.1111/jcpt.12695. View

Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo R . European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2021; 28(4):521-547. DOI: 10.1016/j.cmi.2021.11.025. View

Tiseo G, Brigante G, Giacobbe D, Maraolo A, Gona F, Falcone M . Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for.... Int J Antimicrob Agents. 2022; 60(2):106611. DOI: 10.1016/j.ijantimicag.2022.106611. View

Gatti M, Cojutti P, Pascale R, Tonetti T, Laici C, DellOlio A . Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. Antibiotics (Basel). 2021; 10(11). PMC: 8615220. DOI: 10.3390/antibiotics10111311. View

Adnan S, Ratnam S, Kumar S, Paterson D, Lipman J, Roberts J . Select critically ill patients at risk of augmented renal clearance: experience in a Malaysian intensive care unit. Anaesth Intensive Care. 2014; 42(6):715-22. DOI: 10.1177/0310057X1404200606. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

10.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

11.

Cojutti P, Gatti M, Rinaldi M, Tonetti T, Laici C, Mega C . Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Front Pharmacol. 2021; 12:781892. PMC: 8694396. DOI: 10.3389/fphar.2021.781892. View

12.

Cojutti P, Lazzarotto D, Candoni A, Dubbini M, Zannier M, Fanin R . Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. J Antimicrob Chemother. 2020; 75(10):3029-3037. PMC: 7678894. DOI: 10.1093/jac/dkaa267. View

13.

Jamal J, Roger C, Roberts J . Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics. Anaesth Crit Care Pain Med. 2018; 37(6):515-517. DOI: 10.1016/j.accpm.2018.10.006. View

14.

Udy A, Morton F, Nguyen-Pham S, Jarrett P, Lassig-Smith M, Stuart J . A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. BMC Nephrol. 2013; 14:250. PMC: 3840599. DOI: 10.1186/1471-2369-14-250. View

15.

Cojutti P, Maximova N, Pea F . Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients. Antimicrob Agents Chemother. 2015; 59(9):5535-41. PMC: 4538508. DOI: 10.1128/AAC.00787-15. View

16.

Baptista J, Udy A, Sousa E, Pimentel J, Wang L, Roberts J . A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care. 2011; 15(3):R139. PMC: 3219011. DOI: 10.1186/cc10262. View

17.

Ellis J, Kuti J, Nicolau D . Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther. 2005; 27(11):1820-30. DOI: 10.1016/j.clinthera.2005.11.007. View

18.

Bragadottir G, Redfors B, Ricksten S . Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury--true GFR versus urinary creatinine clearance and estimating equations. Crit Care. 2013; 17(3):R108. PMC: 4056314. DOI: 10.1186/cc12777. View

19.

Al-Dorzi H, Alsadhan A, Almozaini A, Alamri A, Tamim H, Sadat M . The Performance of Equations That Estimate Glomerular Filtration Rate against Measured Urinary Creatinine Clearance in Critically Ill Patients. Crit Care Res Pract. 2021; 2021:5520653. PMC: 8149233. DOI: 10.1155/2021/5520653. View

20.

Levey A, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145(4):247-54. DOI: 10.7326/0003-4819-145-4-200608150-00004. View